T Cell Repertoire Analysis of Immune Mediated Skin Diseases
| Status: | Recruiting |
|---|---|
| Conditions: | Psoriasis, Skin and Soft Tissue Infections, Infectious Disease, Lymphoma |
| Therapuetic Areas: | Dermatology / Plastic Surgery, Immunology / Infectious Diseases, Oncology |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 2/10/2019 |
| Start Date: | January 2007 |
| End Date: | October 2019 |
| Contact: | Emanaual Maverakis, M.D. |
| Email: | emaverakis@ucdavis.edu |
| Phone: | 916-734-1267 |
This study is designed to identify the cells of the immune system that cause skin disease
such as psoriasis and mycosis fungoides. Blood samples from many patients will be compared in
hopes of finding common cells and molecules responsible for skin diseases. Results of this
study will increase our knowledge about immune mediated skin disease.
such as psoriasis and mycosis fungoides. Blood samples from many patients will be compared in
hopes of finding common cells and molecules responsible for skin diseases. Results of this
study will increase our knowledge about immune mediated skin disease.
The aim of the study is to characterized the T cell repertoire of individuals with immune
mediated skin disease (e.g. psoriasis and mycosis fungoides). Peripheral blood with be
collected from volunteers with psoriasis, mycosis fungoides and age matched controls. Fifteen
tablespoons of blood will be collected prior to the initiation of treatment and again after
the patient shows a clinical response to treatment. The time between blood draws will be no
less than 3 months. There will be no more than two blood draws per patient. Blood samples
will be used to determine the patient's HLA haplotype via PCR and DNA sequencing. After the
patient's haplotype has been established the activated T cell repertoire will be analyzed for
clonal expansions. Clonal expansions in the T cell repertoire will be determined by
immunoscope analysis, which is a PCR based technique.
mediated skin disease (e.g. psoriasis and mycosis fungoides). Peripheral blood with be
collected from volunteers with psoriasis, mycosis fungoides and age matched controls. Fifteen
tablespoons of blood will be collected prior to the initiation of treatment and again after
the patient shows a clinical response to treatment. The time between blood draws will be no
less than 3 months. There will be no more than two blood draws per patient. Blood samples
will be used to determine the patient's HLA haplotype via PCR and DNA sequencing. After the
patient's haplotype has been established the activated T cell repertoire will be analyzed for
clonal expansions. Clonal expansions in the T cell repertoire will be determined by
immunoscope analysis, which is a PCR based technique.
Inclusion Criteria:
- Have an immune mediated skin disease, such as psoriasis or mycosis fungoides
- Are not taking immunosuppressive medications, which may interfere with T cell
analysis.
Exclusion Criteria:
- are taking immunosuppressive medications, which may interfere with T cell analysis
We found this trial at
1
site
Sacramento, California 95816
Principal Investigator: Emanual Maverakis, M.D.
Phone: 916-734-1267
Click here to add this to my saved trials
